281 related articles for article (PubMed ID: 28453697)
1. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
Dienstmann R; Mason MJ; Sinicrope FA; Phipps AI; Tejpar S; Nesbakken A; Danielsen SA; Sveen A; Buchanan DD; Clendenning M; Rosty C; Bot B; Alberts SR; Milburn Jessup J; Lothe RA; Delorenzi M; Newcomb PA; Sargent D; Guinney J
Ann Oncol; 2017 May; 28(5):1023-1031. PubMed ID: 28453697
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
3. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
5. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
7. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
8. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH
Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer.
Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT
Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
11. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
13. Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer.
Liu Q; Ma Y; Luo D; Cai S; Li Q; Li X
Int J Colorectal Dis; 2018 Aug; 33(8):1107-1114. PubMed ID: 29770845
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
16. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
[No Abstract] [Full Text] [Related]
18. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
